文献速递神经眼科

水通道蛋白4和髓鞘少突胶质细胞糖蛋白自身抗体状态预测复发性视神经炎预后

Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
PubMed 文献 · Ophthalmology · 2018-04-30

该横断面队列研究纳入246例复发性视神经炎患者,检测水通道蛋白4 IgG和MOG IgG1血清状态。32%患者检出胶质自身抗体(水通道蛋白4 IgG 19%,MOG IgG1 13%)。水通道蛋白4 IgG阳性预示比MOG IgG1阳性、双血清阴性或多发性硬化诊断更差的视力结局;MOG IgG1与更高复发率但更好视力结局相关。

要点

  • 复发性视神经炎患者中32%检出胶质自身抗体,水通道蛋白4 IgG占19%,MOG IgG1占13%。
  • 水通道蛋白4 IgG阳性患者视力结局最差,5年严重视力丧失估计达59%。
  • MOG IgG1阳性患者年复发率最高(1.2),但视力结局较好。

核心结论

  • 胶质自身抗体(MOG IgG1或水通道蛋白4 IgG)见于三分之一的复发性视神经炎患者。
  • 水通道蛋白4 IgG血清阳性预示比MOG IgG1血清阳性、双血清阴性或多发性硬化诊断更差的视力结局。
  • MOG IgG1与更高复发率但更好视力结局相关。

研究设计与样本

  • 横断面队列研究,通过Mayo Clinic计算机化中央诊断索引(2000年1月至2017年3月)搜索确定患者。
  • 纳入246例符合以下标准的患者:初次寻求治疗至少连续2次视神经炎发作,且有血清可供检测。
  • 采用经内部验证的流式细胞术检测血清水通道蛋白4 IgG和MOG IgG1,使用转染M1水通道蛋白4或全长MOG的活HEK293细胞。

主要发现

  • 246例复发性视神经炎患者中,32%检出胶质自身抗体(水通道蛋白4 IgG 19%,MOG IgG1 13%)。
  • 仅复发性视神经炎队列中,双血清阴性(特发性)110例(59%),MOG IgG1阳性27例(15%,其中4例为慢性复发性炎性视神经病),多发性硬化25例(13%),水通道蛋白4 IgG阳性24例(13%)。
  • 复发性视神经炎附加后续其他炎性脱髓鞘发作队列中,水通道蛋白4 IgG阳性23例(38%),多发性硬化22例(37%),双血清阴性11例(18%),MOG IgG1阳性4例(7%)。
  • 仅复发性视神经炎组年复发率:MOG IgG1阳性患者1.2,双血清阴性患者0.7,水通道蛋白4 IgG阳性患者0.6,多发性硬化患者0.4(P = 0.005)。
  • 仅复发性视神经炎组最严重发作最低点时中位视力:水通道蛋白4 IgG阳性患者为手动,MOG IgG1阳性患者介于数指与手动之间,特发性患者20/800,多发性硬化患者20/100(P = 0.02)。

关键数值与推荐

  • 仅复发性视神经炎队列受累眼末次随访中位视力:水通道蛋白4 IgG阳性患者为数指,特发性患者20/40,多发性硬化和MOG IgG1阳性患者20/25(P = 0.006)。
  • 视神经炎发病后5年,估计严重视力丧失比例:水通道蛋白4 IgG阳性患者59%,特发性患者22%,MOG IgG1阳性患者12%,多发性硬化患者8%。

临床怎么用

  • 对复发性视神经炎患者应检测水通道蛋白4 IgG和MOG IgG1血清状态以协助判断预后。
  • 水通道蛋白4 IgG阳性提示更差视力结局,MOG IgG1阳性提示更高复发率但较好视力结局。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the aquaporin-4 and myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG) serostatus and visual outcomes in patients with recurrent optic neuritis (rON) initially seeking treatment. DESIGN: Cross-sectional cohort study. PARTICIPANTS: The study identified patients by searching the Mayo Clinic computerized central diagnostic index (January 2000-March 2017). The 246 eligible patients fulfilled the following criteria: (1) initially seeking treatment for at least 2 consecutive episodes of optic neuritis (ON) and (2) serum available for testing. METHODS: Serum was tested for aquaporin-4 IgG and MOG IgG1 using an in-house validated flow cytometric assay using live HEK293 cells transfected with M1 aquaporin-4 or full-length MOG. MAIN OUTCOMES MEASURES: Aquaporin-4 IgG and MOG IgG1 serostatus, clinical characteristics, and visual outcomes. RESULTS: Among 246 patients with rON at presentation, glial autoantibodies were detected in 32% (aquaporin-4 IgG, 19%; MOG IgG1, 13%); 186 patients had rON only and 60 patients had rON with subsequent additional inflammatory demyelinating attacks (rON-plus group). The rON-only cohort comprised the following: double seronegative (idiopathic), 110 patients (59%); MOG IgG1 positive, 27 patients (15%; 4 with chronic relapsing inflammatory optic neuropathy); multiple sclerosis (MS), 25 patients (13%); and aquaporin-4 IgG positive, 24 patients (13%). The rON-plus cohort comprised the following: aquaporin-4 IgG positive, 23 patients (38%); MS, 22 patients (37%); double seronegative, 11 patients (18%); and MOG IgG1 positive, 4 patients (7%). The annualized relapse rate for the rON-only group was 1.2 for MOG IgG1-positive patients, 0.7 for double-seronegative patients, 0.6 for aquaporin-4 IgG-positive patients, and 0.4 for MS patients (P = 0.005). The median visual acuity (VA) of patients with the worst rON-only attack at nadir were hand movements in aquaporin-4 IgG-positive patients, between counting fingers and hand movements in MOG IgG1-positive patients, 20/800 in idiopathic patients, and 20/100 in MS patients (P = 0.02). The median VA at last follow-up for affected eyes of the rON-only cohort were counting fingers for aquaporin-4 IgG-positive patients, 20/40 for idiopathic patients, 20/25 for MS patients and MOG IgG1-positive patients (P = 0.006). At 5 years after ON onset, 59% of aquaporin-4 IgG-positive patients, 22% of idiopathic patients, 12% of MOG IgG1-positive patients, and 8% of MS patients were estimated to have severe visual loss. CONCLUSIONS: Glial autoantibodies (MOG IgG1 or aquaporin-4 IgG) are found in one third of all patients with rON. Aquaporin-4 IgG seropositivity predicts a worse visual outcome than MOG IgG1 seropositivity, double seronegativity, or MS diagnosis. Myelin oligodendrocyte glycoprotein IgG1 is associated with a greater relapse rate but better visual outcomes.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Jitprapaikulsan J, Chen JJ, Flanagan EP, et al. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. Ophthalmology. 2018. PMID: 29716788. doi:10.1016/j.ophtha.2018.03.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。